Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sunitinib plus Erlotinib in Advanced NSCLC
NCT00457392Phase 3Completed
- Sponsor
- Pfizer
- Start
- Jul 2007
- Primary completion
- Jul 2010
- Modality
- Small Molecules
- Countries
- 26
01
Overview
Phase 3, randomised, double-blind trial in non-small cell lung cancer (NSCLC) comparing Erlotinib + Sunitinib with Erlotinib + Placebo (2 arms). Primary endpoint: Overall Survival. Started Jul 2007; status: completed.
02
Drugs
sunitinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00457392.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00457392.